Clinical trials: Recurrent Herpes Simplex
Herpes Labialis
Open Label Safety Study of Xerese Cream in the Treatment of Recurrent Herpes Labialis in Children 6-11 Years Old
To test the safety of Xerese (acyclovir and hydrocortisone)Cream 5%/1% for the treatment of recurrent cold sores in children ages 6-11yrs after 5 days of treatment.
- Trial name
- NCT01574612
- Testing
- acyclovir/hydrocortisone cream
- Where
- 10 sites in United States
- Volunteers
- 54 people
- Sponsor
- Meda Pharmaceuticals
Genital Herpes
Efficacy and Safety of Famciclovir 1-day Treatment Compared to 3-day Treatment With Valacyclovir in Adults With Recurrent Genital Herpes
This study will assess the safety and efficacy of one-day famciclovir (1000 mg twice a day (b.i.d)) in reducing the duration of genital herpes lesions and the associated symptoms compared to three-day treatment with valacyclovir…
- Trial name
- NCT00306787
- Testing
- Famciclovir, Valacyclovir
- Where
- 66 sites in United States, Australia and 2 more
- Volunteers
- 1,179 people
- Sponsor
- Novartis Pharmaceuticals
Herpes Labialis
Safety and Pharmacokinetics of Famciclovir Single 1500 mg Dose in Adolescents With Recurrent Herpes Labialis
This study will assess the safety, tolerability of a single 1500 mg dose of famciclovir in 50 adolescents with recurrent herpes labialis.
- Trial name
- NCT00878072
- Testing
- Famciclovir
- Where
- 12 sites in United States
- Volunteers
- 53 people
- Sponsor
- Novartis Pharmaceuticals
HSV
Evaluating Benzoyl Peroxide for Preventing Recurrence of HSV-1 Outbreaks With Rescue Crossover Option
Here's a clear, concise, and accurate brief summary suitable for your ClinicalTrials.gov PRS submission: Brief Summary: This randomized, double-blind, placebo-controlled clinical trial evaluates the effectiveness of topical…
- Trial name
- NCT07032649
- Testing
- Benzoyl Peroxide 10% Bar
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- Greg Bew
Recurrent Genital Herpes Simplex Type 2
A Study to Assess the Safety, Pharmacokinetics, and Tolerability of ABI-1179 in Healthy Subjects and in Subjects Seropositive for HSV-2 With Recurrent Genital Herpes
This study is designed to assess safety, tolerability, and pharmacokinetics (PK) of single ascending dose (SAD) of ABI-1179 in Part A in healthy participants and multiple-ascending doses (MAD) of ABI-1179 in Part B in…
- Trial name
- NCT06698575
- Testing
- ABI-1179
- Where
- 18 sites in United States, Australia and 1 more
- Volunteers
- 103 people, healthy volunteers welcome
- Sponsor
- Assembly Biosciences
Recurrent Genital Herpes Simplex Type 2
A Study to Assess the Safety, Pharmacokinetics, and Antiviral Activity of ABI-5366 in Healthy Participants and Participants Seropositive for HSV-2 With Recurrent Genital Herpes
This study is designed to assess safety, tolerability, and pharmacokinetics (PK) of single ascending dose (SAD) of ABI-5366 in Part A in healthy participants and multiple-ascending doses (MAD) of ABI-5366 in Part B in…
- Trial name
- NCT06385327
- Testing
- ABI-5366
- Where
- 15 sites in Australia, New Zealand
- Volunteers
- 115 people, healthy volunteers welcome
- Sponsor
- Assembly Biosciences
Cold Sore
A Comparative Study of the Efficacy of Penciclovir 10mg/g (1%) Cream in Preventing the Appearance of Classical Lesion in Recurrent Cold Sore Sufferers
Comparison of the efficacy of penciclovir 10 mg/g (1%) cream with that of vehicle at 72 hours in preventing the appearance of classical lesions following prodromal symptoms (tingling or burning sensation) based on thermographic…
- Trial name
- NCT00820534
- Testing
- Penciclovir
- Where
- United Kingdom
- Volunteers
- 126 people
- Sponsor
- Novartis
Genital Herpes
A Phase 2 Trial to Evaluate the Safety and Efficacy of UB-621
To evaluate the efficacy of two dose levels of UB-621 administration in reducing the HSV-2 genital shedding rate in patients with recurrent genital HSV-2 infection.
- Trial name
- NCT03595995
- Testing
- UB-621
- Volunteers
- 80 people
- Sponsor
- United BioPharma
Infections, Herpesviridae
VALTREX Once Daily For Viral Shedding In Herpes Simplex Virus 2 (HSV-2) Seropositive Subjects. VALTREX® Tablet is a Trademark of GlaxoSmithKline Group of Companies.
Eligible subjects will be randomized to receive VALTREX® tablet 1g or placebo once daily for 60 days in a two-way crossover study with a washout period of 7 days between treatment periods.
- Trial name
- NCT00116844
- Testing
- Valaciclovir
- Where
- 17 sites in United States
- Volunteers
- 73 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Herpes Simplex, HIV Infections
A Study to Compare the Efficacy and Safety of Valacyclovir Hydrochloride ( 256U87 ) Versus Acyclovir in the Treatment of Recurrent Anogenital Herpes Infections in HIV Infected Patients
To evaluate the safety and efficacy of oral valacyclovir hydrochloride (256U87) vs. acyclovir in the treatment of recurrent anogenital herpes in HIV-infected patients (CD4 greater than or equal to 100).
- Trial name
- NCT00002000
- Testing
- Valacyclovir hydrochloride, Acyclovir
- Where
- 22 sites in United States
- Sponsor
- Glaxo Wellcome
Herpes Labialis, Cold Sore
Double-blind, Vehicle-controlled Study of the Efficacy and Safety of SADBE in Subjects With Recurrent Herpes Labialis
This study evaluates the safety and efficacy of SADBE in the prevention of recurrent herpes labialis in adults. Two-thirds of the participants will receive a SADBE solution, while the other third will receive only the vehicle as…
- Trial name
- P2a (NCT02965781)
- Testing
- SADBE
- Where
- 5 sites in United States
- Volunteers
- 139 people
- Sponsor
- Squarex, LLC
Herpes Genitalis
A Study With ASP2151 in Subjects With Recurrent Episodes of Genital Herpes
A study of ASP2151 in subjects with recurrent outbreaks of genital herpes.
- Trial name
- NCT00486200
- Testing
- ASP2151, valacyclovir
- Where
- 25 sites in United States
- Volunteers
- 695 people
- Sponsor
- Astellas Pharma Inc
Herpes Labialis
Non-inferiority Comparison of Efficacy and Safety of Penciclovir 10mg/g to Acyclovir 50mg/g in the Treatment of Recurrent Herpes Labialis
Herpes labialis is the most common recurrent manifestation of herpes simplex. The purpose of this study is to check the non-inferiority efficacy and safety of penciclovir 10mg/g as treatment for Herpes Labialis in comparison to…
- Trial name
- NCT01257074
- Testing
- Acyclovir 50mg/g, Penciclovir 10mg/g
- Where
- Brazil
- Volunteers
- 76 people
- Sponsor
- EMS
Herpes Simplex
A Study on the Reactogenicity, Safety, Immune Response, and Efficacy of a Targeted Immunotherapy Against HSV in Healthy Participants Aged 18-40 Years or in Participants Aged 18-60 Years With Recurrent Genital Herpes
The purpose of this first-time-in-human (FTiH) study is to evaluate the reactogenicity, safety, immune response, and efficacy of an investigational herpes simplex virus (HSV)-targeted immunotherapy (TI).
- Trial name
- NCT05298254
- Testing
- Non-adjuvanted HSV formulation 1, Non-adjuvanted HSV formulation 2, Non-adjuvanted HSV formulation 3
- Where
- 30 sites in United States, Australia and 6 more
- Volunteers
- 505 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Herpes Labialis
Safety Study of ME-609 for Treatment of Herpes Simplex Labialis in Adolescents
The Purpose of this study is to evaluate the safety of ME-609 for the treatment of recurrent herpes labialis in adolescents.
- Trial name
- NCT00375570
- Testing
- ME-609
- Volunteers
- 254 people
- Sponsor
- Medivir
Herpes Simplex, HIV Infections
Double-Blind Placebo-Controlled Study Comparing the Combination of 15% SP-303 Gel With Acyclovir Versus Acyclovir Alone for the Treatment of Recurrent Herpes Simplex Virus (HSV) Infections in Subjects With Acquired Immunodeficiency Syndrome (AIDS)
To evaluate the safety of topically applied SP-303 gel and to compare the efficacy of SP-303 gel in combination with acyclovir, relative to acyclovir alone, for the treatment of recurrent Herpes Simplex Virus (HSV) 1 and 2…
- Trial name
- NCT00002186
- Testing
- Crofelemer, Acyclovir
- Where
- 34 sites in United States, Puerto Rico
- Volunteers
- 400 people
- Sponsor
- Shaman Pharmaceuticals